




The relative strengths and weaknesses of Corvus Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Corvus Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 101% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	27,956
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,869
Liabilities, Non-Current	0
Other Assets	17,361
Other Compr. Net Income	-404
Other Expenses	0
Other Liabilities	0
Other Net Income	-3,622
Other Revenues	0
Property and Equipment	236
Research and Development	16,526
Selling, General and Administrative Expense	6,881

Output Variable	Value in 1000 USD
Assets	45,553
Liabilities	6,869
Expenses	23,407
Revenues	0
Stockholders Equity	38,684
Net Income	-27,029
Comprehensive Net Income	-27,231
BaseVar	39,928
ECR before LimitedLiability	218%
Economic Capital Ratio	314%